9th Neuropsychiatric Drug Development Summit

The 9th Neuropsychiatric Drug Development Summit focuses on advancing neuropsychiatric drug development through precision psychiatry approaches, integrating biology-first frameworks, AI-enabled biomarker discovery, and next-generation therapeutic innovation across mental health disorders.

Key Topics

• Precision psychiatry frameworks and biology-first drug development strategies
• AI-driven neurotherapeutics and computational psychiatry applications
• Neuropsychiatric clinical trial design, endpoints, and Phase 1–3 development challenges
• EEG, sleep, and digital biomarkers for diagnosis and patient stratification
• Glutamatergic, orexin, muscarinic, and serotonin receptor-targeted therapeutics
• Neuroplasticity mechanisms in mood, psychosis, and cognitive disorders
• Regulatory strategy and commercialization of interventional psychiatry innovations
• Genetics-anchored models and translational neuroscience approaches
• Early-stage efficacy measurement using RWD, PROs, and multimodal data
• Investment trends and strategic capital shaping neuropsychiatric innovation

Who should Attend

• Neuroscience and neuropsychiatric drug developers
• Clinical researchers in psychiatry and neurology
• Pharmaceutical and biotech R&D leaders
• AI and computational biology specialists in healthcare
• Clinical trial designers and translational medicine experts
• Regulatory affairs and drug approval professionals
• Biomarker and diagnostics developers
• Investors and venture capital professionals in biotech
• Academic researchers in neuroscience and mental health
• Medical professionals in psychiatry and neurotherapy